DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia
- 23 June 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 32 (1), 30-37
- https://doi.org/10.1038/leu.2017.200
Abstract
We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 3A-R882H/-R882C mutations (DNMT3A(mut)). MRD was determined by real-time quantitative PCR (RQ-PCR) in 1494 samples of 181 DNMT3A(mut) patients. At the time of diagnosis, DNMT3A(mut) transcript levels did not correlate with presenting clinical characteristics and concurrent gene mutations as well as the survival end points. In Cox regression analyses, bone marrow (BM) DNMT3A(mut) transcript levels (log10-transformed continuous variable) were not associated with the rate of relapse or death. DNMT3A(mut) transcript levels were significantly higher in BM than in blood after induction I (P = 0.01), induction II (P = 0.05), consolidation I (P = 0.004) and consolidation II (P = 0.008). With regard to the clinically relevant MRD time points, after two cycles of induction and at the end of therapy, DNMT3A(mut) transcript levels had no impact on the end point remission duration and overall survival. Of note, only a minority of the patients achieved RQ-PCR negativity, whereas most had constantly high DNMT3A(mut) transcript levels, a finding which is consistent with the persistence of clonal hematopoiesis in hematological remission.Keywords
This publication has 50 references indexed in Scilit:
- Genomics of Acute Myeloid Leukemia Diagnosis and PathwaysJournal of Clinical Oncology, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with PM-Rara, CBFB-MYH11, and RUNX1-RUNX1T1: A Study on 600 PatientsBlood, 2015
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Hematology-American Society Hematology Education Program, 2014
- Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaBlood, 2013
- Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trialBlood, 2012
- Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2009